Evolution of Gray Matter Atrophy Over 4 Years in Observational Study of Early IFNbeta-1a I.M. Treatment in High Risk Subjects After Clinically Isolated Syndrome (SET Substudy)

Trial Profile

Evolution of Gray Matter Atrophy Over 4 Years in Observational Study of Early IFNbeta-1a I.M. Treatment in High Risk Subjects After Clinically Isolated Syndrome (SET Substudy)

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Jun 2015

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Demyelinating disorders
  • Focus Therapeutic Use
  • Acronyms SET Substudy
  • Most Recent Events

    • 08 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 11 May 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top